Yarina Plus tablets p / o, No. 28

Contraception intended primarily for women with symptoms of hormone-dependent fluid retention.
Contraception and treatment of moderate acne (acne vulgaris).
Contraception for women with folate deficiency.

The tablets should be taken orally in the order indicated on the package, every day at the same time, without chewing, with a little water. Take 1 tablet / day continuously for 28 days. Taking pills from the next package begins immediately after the completion of the previous one.

Taking the drug Yarina Plus begins on the 1st day of the menstrual cycle (i.e., on the 1st day of menstrual bleeding).

For one tablet with a combination of active ingredients

Core
Active ingredients: drospirenone (micronized) 3,000 mg; ethinylestradiol betadex clathrate (micronized) in terms of ethinylestradiol 0.030 mg, calcium levomefolate [MetafolinЃ] (micronized) 0.451 mg;
Excipients: lactose monohydrate 45.319 mg, microcrystalline cellulose 24.800 mg, croscarmellose sodium 3,200 mg, hyprolose (5 cP) 1,600 mg, magnesium stearate 1,600 mg.

Sheath
Orange varnish 2.0000 mg or (alternatively): hypromellose (5 cP) 1.0112 mg, macrogol-6000 0.2024 mg, talc 0.2024 mg, titanium dioxide 0.5271 mg, iron dye yellow oxide 0.0446 mg, iron dye red oxide 0.0123 mg.

Composition for one auxiliary vitamin tablet

Core
Active ingredient: calcium levomefolate [MetafolinЃ] (micronized) 0.451 mg;
Excipients: lactose monohydrate 48.349 mg, microcrystalline cellulose 24.800 mg, croscarmellose sodium 3,200 mg, hyprolose (5 cP) 1,600 mg, magnesium stearate 1,600 mg.

Coating
Varnish light orange 2.0000 mg or (alternatively): hypromellose (5 cP) 1.0112 mg, macrogol-6000 0.2024 mg, talc 0.2024 mg, titanium dioxide 0.5723 mg, iron dye yellow oxide 0 , 0089 mg, iron dye red oxide 0.0028 mg.

Thrombosis (venous and arterial) and thromboembolism at present or in history (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke), cerebrovascular disorders.
Conditions preceding thrombosis (including transient ischemic attacks, angina pectoris) at present or in history.
The presence of multiple or severe risk factors for venous or arterial thrombosis.
Migraine with focal neurological symptoms at present or in history.
Diabetes mellitus with vascular complications.
Liver failure and severe liver disease (until liver function tests are normalized).
Severe and / or acute renal failure.
Liver tumors (benign or malignant), current or history.
Identified hormone-dependent malignant neoplasms (including the genitals or mammary glands) or suspicion of them.
Vaginal bleeding of unknown origin.
Pregnancy or suspicion of it.
Breastfeeding period.
Hypersensitivity or intolerance to any of the components of the drug Yarina Plus.
The drug Yarina Plus contains lactose, therefore it is contraindicated in patients with rare hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

Pharmacological action
Yarina Plus is a low-dose monophasic oral combined estrogen-gestagenic contraceptive preparation, including active tablets and auxiliary vitamin tablets containing calcium levomefolate.
The contraceptive effect of the drug Yarina Plus is mainly carried out by suppressing ovulation and increasing the viscosity of cervical mucus.

Indications
Contraception intended primarily for women with symptoms of hormone-dependent fluid retention.
Contraception and treatment of moderate acne (acne vulgaris).
Contraception for women with folate deficiency.

Contraindications
Current or history of thrombosis (venous and arterial) and thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke), cerebrovascular disorders.
Conditions preceding thrombosis (including transient ischemic attacks, angina pectoris) at present or in history.
The presence of multiple or severe risk factors for venous or arterial thrombosis.
Migraine with focal neurological symptoms at present or in history.
Diabetes mellitus with vascular complications.
Liver failure and severe liver disease (until liver function tests are normalized).
Severe and / or acute renal failure.
Liver tumors (benign or malignant), current or history.
Identified hormone-dependent malignant neoplasms (including the genitals or mammary glands) or suspicion of them.
Vaginal bleeding of unknown origin.
Pregnancy or suspicion of it.
Breastfeeding period.
Hypersensitivity or intolerance to any of the components of the drug Yarina Plus.
The drug Yarina Plus contains lactose, therefore it is contraindicated in patients with rare hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

Method of administration and dosage
Tablets should be taken orally in the order indicated on the package, every day at the same time, without chewing, with a little water. Take 1 tablet / day continuously for 28 days. Taking pills from the next package begins immediately after the completion of the previous one.

Taking the drug Yarina Plus begins on the 1st day of the menstrual cycle (i.e., on the 1st day of menstrual bleeding).

Side effects
From the digestive system: nausea, vomiting.
From the reproductive system: changes in vaginal secretion.
From the endocrine system: engorgement, soreness of the mammary glands, secretion from them; change in body weight, change in libido.
From the side of the central nervous system: decreased mood, headache, migraine.
Others: various skin reactions, poor tolerance of contact lenses, fluid retention in the body, allergic reactions.